Dr. Mark G. Trombetta, MD

Dr. Trombetta practices at Trinity Health System in Steubenville, Ohio, part of University of Pittsburgh Medical Center.

Dr. Trombetta's NPI, 1073515789, was assigned on August 12, 2005. Dr. Trombetta graduated from Hahnemann University College of Medicine in 1985. Dr. Trombetta holds Pennsylvania license MD036487E.

Dr. Trombetta's primary practice is Trinity Health System, at 380 Summit Avenue, Steubenville, OH 43952 in Jefferson County. The practice phone is (740) 264-7212. Dr. Trombetta also practices at Trinity Medical Center West, 4000 Johnson Rd, Steubenville, OH 43952.

Dr. Trombetta's primary practice is Trinity Health System in Steubenville, Ohio, part of University of Pittsburgh Medical Center. Dr. Trombetta is also affiliated with Allegheny General Hospital. The medical group on file is AHN Primary Care - Family Med Associates at H+W Pavilion Bethel Park. Dmand AI also links Dr. Trombetta to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Trombetta practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Trombetta's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Trombetta is licensed in Pennsylvania.

CMS data shows 1,434 Medicare services from Dr. Trombetta across 13 procedure codes in 2024, for 181 Medicare patients. Medicare paid $101,205 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 181 Medicare patients who saw Dr. Trombetta in 2024. The largest group is 65 to 74, with 97 patients. 75% of them have cancer, and 75% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Trombetta's median patient age at 74, with 47% women.

In 2024, Dr. Trombetta wrote 103 Medicare Part D claims for 53 patients. 97% of them were for generic drugs. CMS names the drug for 50 of them, across 2 drugs with 11 or more claims each, at $308 in total drug cost. In 2023, CMS named 126 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Trombetta for performance year 2024, reported through an alternative payment model (APM). Dr. Trombetta accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 43 papers to Dr. Trombetta, published from 2008 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, Brachytherapy and Mastectomy, Segmental. Dr. Trombetta has published most often in Brachytherapy. Dr. Trombetta's most frequent co-authors are Thomas B. Julian, MD, Athanasios Colonias, MD and Paul Bernard Renz, DO.

Dmand AI links Dr. Trombetta to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Lobular, Lymphatic Metastasis and Carcinoma, Ductal, Breast.

CMS Open Payments shows 121 general payments to Dr. Trombetta from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 70% of the total. Elekta, Inc. paid the most, $1,551.

Dr. Trombetta graduated from Hahnemann University College of Medicine in 1985.